Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Allogene Therapeutics (ALLO) EBIT Margin (2021 - 2025)

Historic EBIT Margin for Allogene Therapeutics (ALLO) over the last 4 years, with Q1 2024 value amounting to 315927.27%.

  • Allogene Therapeutics' EBIT Margin rose 143793900.0% to 315927.27% in Q1 2024 from the same period last year, while for Dec 2024 it was 1241813.64%, marking a year-over-year decrease of 8968273200.0%. This contributed to the annual value of 1241813.64% for FY2024, which is 8968273200.0% down from last year.
  • Allogene Therapeutics' EBIT Margin amounted to 315927.27% in Q1 2024, which was up 143793900.0% from 405280.95% recorded in Q4 2023.
  • Allogene Therapeutics' 5-year EBIT Margin high stood at 2.26% for Q4 2021, and its period low was 405280.95% during Q4 2023.
  • Its 4-year average for EBIT Margin is 232707.56%, with a median of 286345.45% in 2023.
  • Over the last 5 years, Allogene Therapeutics' EBIT Margin had its largest YoY gain of 417170500bps in 2022, and its largest YoY loss of 2000000000bps in 2022.
  • Allogene Therapeutics' EBIT Margin (Quarter) stood at 2.26% in 2021, then plummeted by -16431036bps to 370750.0% in 2022, then dropped by -9bps to 405280.95% in 2023, then increased by 22bps to 315927.27% in 2024.
  • Its EBIT Margin was 315927.27% in Q1 2024, compared to 405280.95% in Q4 2023 and 286345.45% in Q3 2023.